Vascular disease remains the leading cause of death and disability, the etiology of which often involves atherosclerosis. The current treatment of atherosclerosis by pharmacotherapy has limited therapeutic efficacy. Here we report a biomimetic drug delivery system derived from macrophage membrane coated ROS-...
Reports of statin treatment in the pediatric population revealed no evidence of muscle pathology, with asymptomatic elevation of creatine kinase(CK) levels and symptoms of muscle pain without CK elevation seen equally in subjects and controls in RCTs. By contrast, rare cases of rhabdomyolysis have ...
4B). Strikingly, Vav2−/−ApoE−/−mice had significantly decreased atherosclerosis compared with control mice in the en face analysis of aorta 14 weeks after HFD treatment. The lesion area of ApoE−/− controls was 14.36%, and it dropped to 10.24% in the Vav2−/− ApoE−/...
We evaluated 10-year risk thresholds of 7.5%, 10%, and 15% to determine optimal treatment initiation points. The simulated regimens aligned with the strategies outlined in the guidelines, utilizing the China-PAR risk function for treatment initiation. Additionally, simulations without treatment were ...
In the study, they observed a decrease in the amount of inflammation and a decrease in the amount of drug in the plaque, which indicates the positive effect of this type of treatment on controlling the stability of the plaque. The synthesis of small-scale metal–organic frameworks (MOFs) ...
7 Atherosclerosis Treatment The American Heart Association provides atherosclerosis treatment guidelines to health care providers and their patients.5 These guidelines are intended to prevent fatalities from atherosclerosis, nonfatal heart attacks, and damage to heart function, which could lead to heart fa...
Japan ASi. Japan Atherosclerosis Society (JAS) guidelines for diagnosis and treatment of 1 atherosclerotic cardiovascular disease. Tokyo: JAS; 2002. 2 [34] Shima K, Kuwajima M. Standardization for glycohemoglobin (HbA1c) measurements 3 and its evaluation. Nippon Rinsho. 1998;56 Suppl 3:59-67....
Two populations were studied in this analysis: 389 529 individuals in the primary prevention group who were not taking lipid-lowering therapy and 40 430 patients with established atherosclerosis who were receiving statin treatment. Exposures ApoB, non–high-density lipoprotein cholesterol (HDL-C)...
select article Over 30 years of elaborate experience in LDL apheresis: An effective and well-tolerated treatment option for specific patient subgroups Conference abstractNo access Over 30 years of elaborate experience in LDL apheresis: An effective and well-tolerated treatment option for specific patient...
In a 2006 MESA study that used the Third Report of the Adult Treatment Panel of the National Cholesterol Education Program to evaluate dyslipidemia management, men were more likely than women to be candidates of drug therapy but were less likely to be treated and have lipid level under control...